Literature DB >> 9916933

CD95 ligand (CD95L) in normal human lymphoid tissues: a subset of plasma cells are prominent producers of CD95L.

J Sträter1, S M Mariani, H Walczak, F G Rücker, F Leithäuser, P H Krammer, P Möller.   

Abstract

CD95(Fas/APO-1)-ligand (CD95L) mediates apoptosis by trimerization of the CD95 receptor on the surface of sensitive cells. In vitro studies have shown CD95L expression mainly by activated T cells and suggested a role for CD95L in the regulation of immune responses. Little is known, however, about the cellular distribution of CD95L in situ in the normal human immune system. We investigated CD95L expression in tissue sections of the thymus, lymph node, spleen, tonsil, and gastrointestinal tract using in situ hybridization and two monoclonal antibodies. In all these organs, cells expressing CD95L message and protein were scarce and comprised scattered lymphocytes, rare nonlymphoid cells, and a subset of epithelioid endothelial cells. Surprisingly, a subset of plasma cells turned out to be the most prominent producers of CD95L, matching the reports on CD95L in myeloma cells. CD95L+ plasma cells were most numerous in the mucosa-associated lymphoid tissue. This also applied to acquired mucosa-associated lymphoid tissue in chronic gastritis in which CD95L+ plasma cells were found scattered in the lamina propria. Our data suggest that plasma cells as yet may be neglected modulators of immune responses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9916933      PMCID: PMC1853438          DOI: 10.1016/S0002-9440(10)65265-0

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  36 in total

1.  Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas.

Authors:  T Brunner; R J Mogil; D LaFace; N J Yoo; A Mahboubi; F Echeverri; S J Martin; W R Force; D H Lynch; C F Ware
Journal:  Nature       Date:  1995-02-02       Impact factor: 49.962

2.  Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.

Authors:  T Suda; T Takahashi; P Golstein; S Nagata
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

3.  Fas ligand-induced apoptosis as a mechanism of immune privilege.

Authors:  T S Griffith; T Brunner; S M Fletcher; D R Green; T A Ferguson
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

4.  Histomorphologic and immunophenotypic spectrum of primary gastro-intestinal B-cell lymphomas.

Authors:  B Mielke; P Möller
Journal:  Int J Cancer       Date:  1991-02-01       Impact factor: 7.396

5.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis.

Authors:  R Watanabe-Fukunaga; C I Brannan; N G Copeland; N A Jenkins; S Nagata
Journal:  Nature       Date:  1992-03-26       Impact factor: 49.962

Review 6.  Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease.

Authors:  P L Cohen; R A Eisenberg
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

7.  Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand.

Authors:  T Takahashi; M Tanaka; C I Brannan; N A Jenkins; N G Copeland; T Suda; S Nagata
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

8.  Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)

Authors:  J Dhein; H Walczak; C Bäumler; K M Debatin; P H Krammer
Journal:  Nature       Date:  1995-02-02       Impact factor: 49.962

Review 9.  The Fas death factor.

Authors:  S Nagata; P Golstein
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

10.  Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.

Authors:  S T Ju; D J Panka; H Cui; R Ettinger; M el-Khatib; D H Sherr; B Z Stanger; A Marshak-Rothstein
Journal:  Nature       Date:  1995-02-02       Impact factor: 49.962

View more
  8 in total

1.  Endothelial Fas-Ligand in Inflammatory Bowel Diseases and in Acute Appendicitis.

Authors:  Tuomo S Kokkonen; Tuomo J Karttunen
Journal:  J Histochem Cytochem       Date:  2015-09-15       Impact factor: 2.479

Review 2.  Killer B lymphocytes: the evidence and the potential.

Authors:  Steven K Lundy
Journal:  Inflamm Res       Date:  2009-03-05       Impact factor: 4.575

3.  Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10.

Authors:  Huimin Tao; Lin Lu; Yang Xia; Fu Dai; Yi Wang; Yangyi Bao; Steven K Lundy; Fumito Ito; Qin Pan; Xiaolian Zhang; Fang Zheng; Guoshun Shu; Bingmu Fang; Jinhong Jiang; Jianchuang Xia; Shiang Huang; Qiao Li; Alfred E Chang
Journal:  Eur J Immunol       Date:  2015-01-21       Impact factor: 5.532

Review 4.  CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: fictions and facts.

Authors:  J Sträter; P Möller
Journal:  Virchows Arch       Date:  2003-02-11       Impact factor: 4.064

Review 5.  Human B-1 cells take the stage.

Authors:  Thomas L Rothstein; Daniel O Griffin; Nichol E Holodick; Tam D Quach; Hiroaki Kaku
Journal:  Ann N Y Acad Sci       Date:  2013-05       Impact factor: 5.691

Review 6.  Immunosuppressive Mechanisms of Regulatory B Cells.

Authors:  Diego Catalán; Miguel Andrés Mansilla; Ashley Ferrier; Lilian Soto; Kristine Oleinika; Juan Carlos Aguillón; Octavio Aravena
Journal:  Front Immunol       Date:  2021-04-29       Impact factor: 7.561

7.  Killer B lymphocytes and their fas ligand positive exosomes as inducers of immune tolerance.

Authors:  Steven K Lundy; Matthew W Klinker; David A Fox
Journal:  Front Immunol       Date:  2015-03-20       Impact factor: 7.561

8.  c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis.

Authors:  Stephan Mathas; Andreas Lietz; Ioannis Anagnostopoulos; Franziska Hummel; Burkhard Wiesner; Martin Janz; Franziska Jundt; Burkhard Hirsch; Korinna Jöhrens-Leder; Hans-Peter Vornlocher; Kurt Bommert; Harald Stein; Bernd Dörken
Journal:  J Exp Med       Date:  2004-04-12       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.